NASDAQ:IOVA Iovance Biotherapeutics (IOVA) Stock Price, News & Analysis $5.91 +0.15 (+2.60%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Iovance Biotherapeutics Stock (NASDAQ:IOVA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get IOVA alerts:Sign Up Key Stats Today's Range$5.79▼$6.0050-Day Range$5.76▼$9.6952-Week Range$5.62▼$18.33Volume6.55 million shsAverage Volume6.07 million shsMarket Capitalization$1.80 billionP/E RatioN/ADividend YieldN/APrice Target$23.00Consensus RatingModerate Buy Company OverviewIovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.Read More… Iovance Biotherapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks83rd Percentile Overall ScoreIOVA MarketRank™: Iovance Biotherapeutics scored higher than 83% of companies evaluated by MarketBeat, and ranked 191st out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingIovance Biotherapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageIovance Biotherapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Iovance Biotherapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Iovance Biotherapeutics are expected to grow in the coming year, from ($1.23) to ($0.85) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Iovance Biotherapeutics is -3.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Iovance Biotherapeutics is -3.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIovance Biotherapeutics has a P/B Ratio of 2.59. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Iovance Biotherapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted24.82% of the float of Iovance Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverIovance Biotherapeutics has a short interest ratio ("days to cover") of 8.9.Change versus previous monthShort interest in Iovance Biotherapeutics has recently increased by 3.34%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldIovance Biotherapeutics does not currently pay a dividend.Dividend GrowthIovance Biotherapeutics does not have a long track record of dividend growth. Sustainability and ESG4.2 / 5Environmental Score-1.09 Percentage of Shares Shorted24.82% of the float of Iovance Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverIovance Biotherapeutics has a short interest ratio ("days to cover") of 8.9.Change versus previous monthShort interest in Iovance Biotherapeutics has recently increased by 3.34%, indicating that investor sentiment is decreasing. News and Social Media2.2 / 5News Sentiment-0.10 News SentimentIovance Biotherapeutics has a news sentiment score of -0.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Iovance Biotherapeutics this week, compared to 7 articles on an average week.Search Interest40 people have searched for IOVA on MarketBeat in the last 30 days. This is an increase of 29% compared to the previous 30 days.MarketBeat Follows28 people have added Iovance Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 40% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Iovance Biotherapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $503,000.00 in company stock.Percentage Held by Insiders12.10% of the stock of Iovance Biotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions77.03% of the stock of Iovance Biotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Iovance Biotherapeutics' insider trading history. Receive IOVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Iovance Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address IOVA Stock News Headlines3 Stocks That Could Turn $1,000 Into $5,000 by 2030January 18 at 6:50 PM | fool.comIovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)January 17 at 5:00 PM | globenewswire.comVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.January 20, 2025 | Porter & Company (Ad)IOVA Stock Touches 52-Week Low at $5.76 Amid Market ChallengesJanuary 16, 2025 | msn.comWells Fargo Remains a Buy on Iovance Biotherapeutics (IOVA)January 16, 2025 | markets.businessinsider.comWells Fargo Remains a Buy on Iovance Biotherapeutics (IOVA)January 16, 2025 | markets.businessinsider.comCancer Drug Maker Iovance Tumbles Toward Worst Week Since November, But Retail Feels Macro Selloff OverblownJanuary 10, 2025 | msn.comIovance Biotherapeutics Shares Are Falling Today: What's Going On?January 10, 2025 | benzinga.comSee More Headlines IOVA Stock Analysis - Frequently Asked Questions How have IOVA shares performed this year? Iovance Biotherapeutics' stock was trading at $7.40 at the beginning of the year. Since then, IOVA shares have decreased by 20.1% and is now trading at $5.91. View the best growth stocks for 2025 here. How were Iovance Biotherapeutics' earnings last quarter? Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) issued its quarterly earnings results on Thursday, November, 7th. The biotechnology company reported ($0.28) earnings per share for the quarter, beating analysts' consensus estimates of ($0.31) by $0.03. The biotechnology company had revenue of $58.56 million for the quarter, compared to the consensus estimate of $53.54 million. Iovance Biotherapeutics had a negative net margin of 451.25% and a negative trailing twelve-month return on equity of 58.43%. Who are Iovance Biotherapeutics' major shareholders? Top institutional shareholders of Iovance Biotherapeutics include Assenagon Asset Management S.A. (0.57%), Hennion & Walsh Asset Management Inc. (0.11%), SG Americas Securities LLC (0.02%) and Clear Harbor Asset Management LLC (0.01%). Insiders that own company stock include Wayne P Rothbaum, Merrill A Mcpeak, Iain D Dukes, Ryan D Maynard and Frederick G Vogt. View institutional ownership trends. How do I buy shares of Iovance Biotherapeutics? Shares of IOVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Iovance Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Iovance Biotherapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), CrowdStrike (CRWD) and ServiceNow (NOW). Company Calendar Last Earnings11/07/2024Today1/20/2025Next Earnings (Estimated)2/26/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IOVA CUSIPN/A CIK1425205 Webwww.iovance.com Phone(650) 260-7120FaxN/AEmployees500Year Founded2013Price Target and Rating Average Stock Price Target$23.00 High Stock Price Target$34.00 Low Stock Price Target$10.00 Potential Upside/Downside+289.2%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($1.49) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-444,040,000.00 Net Margins-451.25% Pretax Margin-458.01% Return on Equity-58.43% Return on Assets-45.48% Debt Debt-to-Equity RatioN/A Current Ratio4.22 Quick Ratio3.90 Sales & Book Value Annual Sales$90.86 million Price / Sales19.82 Cash FlowN/A Price / Cash FlowN/A Book Value$2.28 per share Price / Book2.59Miscellaneous Outstanding Shares304,781,000Free Float267,902,000Market Cap$1.80 billion OptionableOptionable Beta0.57 Social Links (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report This page (NASDAQ:IOVA) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump secret stock already up 339% In this video, you’ll also get nine other Trump-connected investments… All of which we believe could have a...Porter & Company | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredStunning Trump Exec Order LeakedMost people have no clue this unassuming facility exists. Yet the minute Donald Trump takes office... ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Iovance Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Iovance Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.